Registry for cardiac amyloidosis patients in Switzerland
Swiss Cardiac Amyloidosis REgistry (Swiss-CARE)
This study is collecting information from patients with cardiac amyloidosis in Switzerland to see how their condition changes over time and to find out who might benefit from a new treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Insel Gruppe AG, University Hospital Bern Academic / other |
| Locations | 7 sites (Basel and 6 other locations) |
| Trial ID | NCT04776824 on ClinicalTrials.gov |
What this trial studies
This observational study aims to collect and analyze data from patients diagnosed with cardiac transthyretin amyloidosis (ATTR) at the Inselspital Bern. It will utilize cardiac magnetic resonance imaging (CMR) techniques, including feature tracking and T1- and T2-mapping, to identify markers that indicate disease severity and help determine which patients may benefit from TTR stabilization treatment. The study will follow patients over 18 months, with clinical and laboratory assessments conducted every 3-6 months to monitor therapy response and disease progression.
Who should consider this trial
Good fit: Ideal candidates include adults with a confirmed diagnosis of amyloidosis, with or without cardiac involvement.
Not a fit: Patients under 18 years of age or those unable to provide consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve patient selection for TTR stabilization therapy, leading to better treatment outcomes.
How similar studies have performed: While there have been studies on cardiac amyloidosis, this approach focusing on CMR feature tracking and mapping for patient selection is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Confirmed diagnosis of amyloidosis w/wo cardiac involvement * General Consent Exclusion Criteria: * Inability to give consent or existence of a written or documented oral refusal of the data subject.\<18 years of age
Where this trial is running
Basel and 6 other locations
- Usb — Basel, Switzerland (Not_yet_recruiting)
- Department of Cardiology, University Hospital Bern, Inselspital, Bern — Bern, Switzerland (Recruiting)
- Hug — Geneva, Switzerland (Recruiting)
- Chuv — Lausanne, Switzerland (Recruiting)
- Luks — Lucerne, Switzerland (Recruiting)
- Kssg — Sankt Gallen, Switzerland (Recruiting)
- Stadtspital Triemli — Zurich, Switzerland (Recruiting)
Study contacts
- Principal investigator: Christoph Gräni, MD, PhD — Department of Cardiology, University Hospital Bern, Inselspital, Bern
- Study coordinator: Christoph Gräni, MD, PhD
- Email: christoph.graeni@insel.ch
- Phone: +41 31 632 4508
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.